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Background: Methylphenidate (MPH), a psycho-stimulant, is the most widely administered drug for the
pharmacological management of patients with attention deficit hyperactivity disorder (ADHD). This study attempts
to determine whether sustainable improvements occur in neurocognitive function among ADHD patients following
12-month treatment with MPH, at drug-free status. Whether age groups, gender or ADHD subtypes differ in
neurocognitive performance during MPH treatment is also examined.
Methods: Study participants consisted of 103 ADHD patients (mean age: 9.1 ± 1.9 years old) who were drug
naïve or drug free for at least 6 months. The patients were prescribed oral short-acting MPH at each dose
range of 0.3–1.0 mg/kg daily. During 12 months of the study, the patients underwent the test of variables of
attention (TOVA) at the baseline, month 6 and month12. Patients were instructed to not intake MPH for one
week before the second and the third TOVA.
Results: Seventy five patients completed the study. Results of this study indicated that although commission
errors and response sensitivity (d’) significantly improved during MPH treatment for 12 months, omission errors,
response time, response time variability and ADHD score did not. While younger ADHD patients (<9 y/o)
performed better in response time, response time variability, d’ and ADHD score than older ones (≥9 y/o), the
latter more significantly improved in response time than the former during 12 months of treatment.
Additionally, boys improved more than girls in omission error and d’. Moreover, although ADHD subtypes
significantly differed in ADHD score during the treatment, MPH treatment and ADHD subtypes did not interact
with each other for all TOVA indices.
Conclusions: ADHD patients significantly improved in impulsivity and perceptual sensitivity, determined as
TOVA, during MPH treatment for 12 months. Age and gender, yet not ADHD subtypes, appear to influence the
MPH treatment effects in some indices of TOVA. A future study containing a comparison group is suggested to
confirm whether the neurocognitive improvements are attributed to long-term effects of MPH or natural
maturation of patients.
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Attention deficit hyperactivity disorder (ADHD) is a com-
mon neuropsychiatric disorder among children and adoles-
cents, affecting 3% to 10% of all school-age children [1].
Numerous neuropsychological tests suggest that children
inflicted with ADHD have significant cognitive impairments
[2]. The current Diagnostic and Statistical Manual, Fourth
Edition (DSM-IV) [3] classifies ADHD into 3 subtypes: in-
attentive type, hyperactive-impulsive type and combined
type, according to the predominant clinical manifestations
of inattention, hyperactivity, and impulsivity. Despite the
use of neuropsychological methods to identify differentiat-
ing endophenotypes among ADHD patients [4], whether
there are distinct neuropsychological deficits between
ADHD subtypes is a contentious issue [5-7].
Methylphenidate (MPH), a psycho-stimulant, is the
most widely administered drug for the pharmacological
management of ADHD patients [8]. The pharmaco-
logical profile acts in dual mechanisms by inhibiting the
re-uptake of dopamine and norepinephrine [9]. MPH
exerts treatment effects for both behavioral and cogni-
tive dimensions in ADHD patients [10,11]. Numerous
studies indicate that various domains of neurocognitive
function are enhanced under acute MPH challenge in
ADHD patients [12-15]. As is generally assumed, behav-
ioral symptoms or neurocognitive impairment of ADHD
patients returns immediately when the drug effect
diminishes. However, some studies have investigated the
neurocognitive effects over long-term MPH treatment,
with a lack of consensus in those findings. The pilot
study of Aggarwal and Lillystone indicated that the com-
mission errors (yet not omission errors, response time
or variability) significantly ameliorated after stimulant
medication therapy at least for 12 months [16]. Konrad
et al. demonstrated that children with ADHD did not
substantially improve in executive control performance
after long-term MPH treatment [17]. However, that
study was limited by a small sample size. Moreover,
Zhang et al. noted that intelligence quotient of ADHD
patients significantly increased after 6 months of MPH
treatment [18]. In sum, whether long-term prescription
of MPH enhances neurocognitive performance in
ADHD patients remains unclear.
The treatment effects are diverse among ADHD patients,
with some studies attempting to determine the predictors
of treatment outcome [19,20]. Exactly how MPH affects the
neuropsychological profiles between subtypes of ADHD
patients still remains a contentious issue. Several studies
demonstrated that MPH enhanced cognitive performance
equally in patients with ADHD-combined type and
ADHD-inattentive type [21-23]. However, other studies
demonstrated that patients with ADHD-combined type sig-
nificantly improved in behavioral symptoms [24] and ex-
ecutive function performance [25]. Furthermore, althoughsome cross-sectional studies indicated that age and gender
were associated with the neurocognitive functions in
ADHD patients [26,27], whether these factors influence the
long-term treatment effects of MPH remains unclear.
Therefore, this study attempts to determine whether
neurocognitive function among ADHD patients improve
in a sustainable manner during 12 months of treatment
with MPH, at drug-free status. In addition to the main
purpose, we also conduct an explorative analysis to exam-
ine whether age groups, gender or ADHD subtypes differ
in neurocognitive performance during MPH treatment.
Methods
Study participants
ADHD patients between ages of 6 and 16 years old
were recruited from the out-patient Child Psychiatry
Department at Chang Gung Children’s Hospital (Linkou,
Taiwan). The study received approval from the Institu-
tional Review Board of Chang Gung Memorial Hospital.
Written informed consent was obtained from the par-
ents of the patients. ADHD and comorbid disorders
were diagnosed by two senior child psychiatrists, based
on the DSM-IV criteria [3] after structured interviews
with the Chinese version of the Schedule for Affective
Disorder and Schizophrenia for School-Age Children,
epidemiologic version (K-SADS-E) [28]. The Chinese ver-
sion of K-SADS-E was developed by the Child Psychiatry
Research Group in Taiwan [29]. ADHD subjects were clas-
sified as inattentive, hyperactive-impulsive, or combined
type. Patients were excluded from the study if they had a
history of co-morbid pervasive developmental disorders
or mental retardation, as well as those who had a history
of bipolar disorder, psychosis, epilepsy, or brain injury.
Included patients were either newly diagnosed with ADHD
or had an existing diagnosis, yet had not taken ADHD
medication during the previous 6 months or longer.
Measurements
Neurocognitive function of ADHD patients was assessed
using the test of variables of attention (TOVA)-Visual
[30], which is a computerized, continuous performance
test comprising a target stimulus and a non-target
stimulus. Experienced child psychologists conducted
TOVA with individual subjects in a room dedicated to
reducing variability in testing conditions.
The TOVA stimuli are coloured squares with a small
black square within, which is adjacent to either the top
or the bottom edge. The squares with a small inner
square near the top edge are designated targets, and the
ones with the small squares near the bottom edge are
non-targets. The stimuli appear individually and are pre-
sented randomly, based on a determined ratio. The
tested subject was instructed to immediately press a but-
ton after seeing a target and does not respond when a
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is preceded by a practice session for 2.5 minutes. Two
visual stimuli appeared 648 times. The TOVA was
reported to achieve satisfactory levels of reliability and
concurrent validity in Taiwanese children with ADHD
[31]. The indices measured in the TOVA include the
following:
Omission errors: this score is evaluated as the failure to
respond to the target stimulus. Omission error scores
are presented as percentages and are considered to be a
measure of inattention.
Commission errors: this score is measured as an
inappropriate response to the non-target stimulus.
Commission error scores are presented as percentages
and are considered to reflect impulsivity or
disinhibition.
Response time (in msec): this score is determined as the
average of the correct response times. This score
denotes response latency in information processing and
motor response speed.
Response time variability: this score is evaluated as the
standard deviation of the mean of correct response
times. It is a measure of the subject’s inconsistency in
response times.
Response sensitivity (d’): this score is a response
sensitivity score reflecting the ratio of the hit rate to
false alarm rate. This score refers to the accuracy of
target and non-target discrimination and is interpreted
as a measure of perceptual sensitivity.
ADHD score: this score is a composite score generated
by the TOVA program. The score is calculated by
comparing an individual’s performance on the TOVA
to those of an ADHD sample collected by the authors
of the TOVA. The score describes how similar an
individual’s performance is to the ADHD profile.Study procedure
Each subject performed the TOVA 3 times. At the
first TOVA (month 0), all subjects were drug naïve
or had not taken medication for ADHD during the
previous 6 months or longer. Subsequently, ADHD
patients were prescribed oral short-acting methylpheni-
date (MPH) twice or three times daily at each dose
range of 0.3–1.0 mg/kg, based on the severity of their
clinical symptoms as well as their age, height, and body
weight. Concomitant medications were prohibited.
Patient care was performed based on their usual prac-
tice at the out-patient services of the child psychiatry
department. There was no additional behavioral therapy
or family therapy provided during the period of study.
Drug compliance at each visit was confirmed according
to the reports of patients’ caregivers.The second and third TOVA were performed at the
6th and 12th month after treatment with MPH, respect-
ively. Patients were instructed to not intake MPH for
one week before the second and the third TOVA. The
TOVA tests were compared before treatment, 6 months
and 12 months after MPH treatment.
Statistical analysis
Data were analyzed using the statistical software package
SPSS, version 16.0 (SPSS Inc., Chicago, IL, USA). Vari-
ables are presented as either the mean (standard devi-
ation) or frequency. Two-tailed p values of <0.05 were
considered statistically significant.
The TOVA results were reported as standard deviations,
which indicated the extent of deviation from the norm. Vari-
ables between ADHD subtypes at baseline were compared
using the Fisher’s Exact Test and Kruskal Wallis Test. Miss-
ing data at the 6th and 12th months were accounted for by
using the method of last observation carried forward
(LOCF). The longitudinal data were analyzed using a linear
mixed model, with the maximum likelihood estimation
method and auto-regression covariance matrix, as the pri-
mary analytic strategy. To examine the trends of neuro-
cognitive function under MPH treatment within 12 months,
the dependent variables were set as the indices in TOVA.
The age of patients was divided into a categorical variable
based on the median age of 9. This study also investigated
the extent of the differences in changes of performance in
TOVA between age groups, gender and ADHD subtypes,
also by the linear mixed model. The hypothesis that a differ-
ential change occurs in dependent measures over 12 months
is supported by significant interactions of MPH treatment ×
age, gender or ADHD subtypes.
Results
This study recruited 103 ADHD patients (mean age: 9.1 ±
1.9 years). Of the 103 patients, 82 (79.6%) were male and
21 (20.4%) were female. Fifty-four of them were inattentive
type; 5 were hyperactive-impulsive type; and 44 were com-
bined type. The three ADHD subtypes identified at month
0 (pretreatment) did not significantly differ in age, gender,
and indices in TOVA (Table 1). Owing to the small num-
ber of patients with hyperactive-impulsive type, these five
patients were placed with patients with combined type
into further longitudinal analysis.
Among the 103 ADHD patients at the initial visit, 75
patients remained in the study at month 6 and month
12. The mean dose of MPH of the 75 patients at the
endpoint is 19.8 ± 13.2 mg. Among the 28 drop-out
patients, 10 patients withdrawal of consent, and 18
patients lost of follow up. Comparing the remaining
patients with the drop-out patients, there were no sig-
nificant differences in demographic characteristics (age:
t = 0.16, p = 0.877; gender: χ2 = 0.33, p = 0.758; ADHD
Table 1 Age, gender and performance in TOVA for children with ADHD between subtypes at baseline
Inattentive type (n = 54) Hyperactive-impulsive type (n = 5) Combined type (n = 44) Statistic a
Age (years) 9.4 (1.9) 8.8 (1.5) 8.7 (2.0) 3.31 (0.192)
Gender (female/male), n (%) 14 (25.9)/40 (74.1) 0 (0)/5 (100) 7 (15.9)/37 (84.1) 2.19 (0.308)
Omission errors −1.01 (1.52) −1.89 (2.18) −1.11 (1.52) 0.80 (0.672)
Commission errors −0.06 (1.42) −0.37 (1.41) −0.41 (1.60) 4.68 (0.097)
Response time −0.76 (1.25) −0.43 (0.90) −0.96 (1.61) 0.77 (0.682)
Response time variability −0.87 (1.53) −0.95 (0.76) −1.31 (1.45) 1.90 (0.387)
Response sensitivity (d’) −0.74 (0.93) −1.02 (1.02) −0.97 (0.81) 0.94 (0.626)
ADHD score −1.49 (2.94) −1.52 (2.27) −3.32 (3.60) 3.77 (0.152)
Note: TOVA results are reported as standard deviations from the norm; data are expressed as mean (SD) or n (%); a statistical values are expressed as χ2 (p-value)
using Kruskal Wallis Test or Fisher’s Exact Test.
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TOVA (omission errors: t = 0.79, p = 0.434; commission
errors: t = −0.37, p = 0.709; response time: t = −0.49,
p = 0.624; response time variability: t = −1.95, p = 0.054;
response sensitivity (d’) : t = −0.68, p = 0.496; ADHD
score: t = −1.25, p = 0.215).
Of the indices in TOVA, commission errors (F = 3.66,
p = 0.029) and d’ (F = 3.71, p = 0.026) were significantly
improved during 12 months of treatment by MPH in a
clinical setting. Table 2 summarizes the performance in
TOVA at months 0, 6 and 12. Post-hoc tests indicated
that d’ improved significantly (t = 2.71, p = 0.007) after
6 months of treatment with MPH. Compared with data
at month 0, commission errors improved significantly
(t = 2.70, p = 0.008) after 12 months of treatment with
MPH. Additionally, omission errors, response time, res-
ponse time variability and ADHD score at the endpoint did
not significantly improve. Moreover, all indices of TOVA
did not change significantly between months 6 and 12.
Table 3 summarizes the effects of age, gender, ADHD
subtypes and MPH treatment on each index of TOVA.
Younger ADHD patients (<9y/o) performed better in re-
sponse time (t = 2.34, p = 0.020), response time variabil-
ity (t = 2.51, p = 0.013), d’ (t = 2.57, p = 0.011), and
ADHD score (t = 2.77, p = 0.006) than older patients
(≥9 y/o). However, younger patients improved less in
response time (t = −2.72, p = 0.007) than older onesTable 2 TOVA performance for patients with ADHD at baselin
treatment
Month 0 (N = 103) Month 6 (N = 75)
Omission errors −1.09 (1.55) −1.00 (1.47)
Commission errors −0.22 (1.49) 0.01 (1.22)
Response time −0.83 (1.40) −0.75 (1.24)
Response time variability −1.06 (1.47) −0.91 (1.31)
Response sensitivity (d’) −0.85 (0.88) −0.65 (0.92)
ADHD score −2.22 (3.29) −2.00 (3.08)
Note: TOVA results are reported as standard deviations from the norm, and express
expressed as F (p-value) using linear mixed model analysis; NS = non-significant; *pduring 12 months of treatment. In terms of gender, the
gender groups did not significantly differ in any TOVA
index. Nevertheless, male patients more significantly
improved in omission error (t = 2.30, p = 0.022) and d’
(t = 2.41, p = 0.017) than female patients during treat-
ment. As for the effects of ADHD subtypes, ADHD
subtypes (t = 2.21, p = 0.029) significantly differed in
ADHD score during 12 months of treatment with
MPH. Moreover, ADHD subtypes did not significantly
differ in other indices of TOVA. Furthermore, all TOVA
indices revealed no effects of interaction between MPH
treatment and ADHD subtypes.
Discussion
This study demonstrates that commission errors and d’
significantly improved during MPH treatment, while the
other indices of TOVA did not. This finding suggests that
ADHD patients have an improved ability of impulse con-
trol and perceptual sensitivity, but not sustained attention
or response speed, under long-term MPH treatment. Our
previous study has established that one dose of MPH
produced more effects on impulsivity than on inattention
in children with ADHD [13]. A previous study involving
the long-term effects of MPH on TOVA performance,
in which participants were also tested off the drug,
also demonstrated a compatible finding [16]. Similarly, a
6-month open-label study showed that children withe, and at months 6 and month 12 after methylphenidate
Month 12 (N = 75) Statistic a Post-hoc tests
−1.17 (1.61) 0.90 (0.408) NS
0.16 (1.05) 3.66 (0.029)* Month 12 > Month 0 **
−0.79 (1.23) 0.43 (0.654) NS
−0.99 (1.36) 1.17 (0.315) NS
−0.67 (0.93) 3.71 (0.026)* Month 6 > Month 0 **
−2.09 (3.23) 0.95 (0.390) NS
ed as mean (SD); month 0 data is pretreatment data; a statistical values are
<0.05, **p<0.01.













Age (<9 years vs. ≥9 years) −0.30 (0.764) 0.51 (0.610) 2.34 (0.020)* 2.51 (0.013)* 2.57 (0.011)* 2.77 (0.006)**
Gender (female vs. male) −0.18 (0.858) 0.91 (0.365) 0.44 (0.658) 0.96 (0.336) 0.50 (0.621) −0.10 (0.924)
ADHD subtypes a 0.17 (0.862) 1.19 (0.234) 0.79 (0.432) 1.50 (0.136) 1.62 (0.107) 2.21 (0.029)*
MPH treatment −0.14 (0.890) 2.02 (0.044)* 1.57 (0.119) 1.16 (0.247) 2.24 (0.026)* 1.42 (0.158)
Age × MPH treatment −0.16 (0.870) 0.58 (0.561) −2.72 (0.007)** −1.24 (0.218) −0.76 (0.446) −1.61 (0.110)
Gender × MPH treatment −2.30 (0.022)* −1.39 (0.166) 0.51 (0.611) −0.76 (0.447) −2.41 (0.017)* −0.04 (0.971)
ADHD subtypes × MPH
treatment
0.91 (0.363) −0.14 (0.886) −0.33 (0.741) −0.07 (0.943) −0.01 (0.990) −0.99 (0.322)
Note: Data are expressed as statistical values, t (p-value), using linear mixed model analysis; a ADHD subtypes: inattentive type vs. hyperactive-impulsive type and
combined type; *p<0.05, **p<0.01.
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dimensions than in attention dimensions of the Conners’
Continuous Performance Test, which were tested while
on the medication [23]. Moreover, another study found
that neurocognitive effects of MPH were more promin-
ent on tasks without an executive function component
than with an executive function component [8]. In sum-
mary, the stimulant-related cognitive enhancements
may be discrepant in different dimensions of neurocog-
nitive function.
Results of this study also suggest that the effects of
MPH on two TOVA indices can be sustained for at least
12 months, even when ADHD patients are tested at
drug-free status. These results support the conclusion of
a recent review that MPH is continuously effective for
an extended period [10]. Some long-term follow-up
studies for ADHD patients have found that treatment
with medication in childhood may improve some mea-
sures of academic achievements [32,33]. Biederman
et al. demonstrated that non-medicated ADHD patients
have a more pervasive pattern of cognitive deficits than
medicated ADHD ones [34]. In contrast to the studies in
self-selected naturalistic settings, the Multimodal Treat-
ment study of children with ADHD (MTA), which con-
ducted with a randomized-controlled design, reported
contradictory findings. Although the benefits of stimu-
lant medications persisted for 14 months [35], the earlier
advantage of having continuous intake of medication
for 14 months is no longer apparent at the 36-month
follow-up [36]. Therefore, the likelihood that selection
bias inflated the long-term neurocognitive effects of
MPH in previous studies can not be ruled out. Further
research is warranted to clarify whether the MPH-
related cognitive enhancements exist during long-term
treatment, even when the drug effect diminishes.
This study also examines whether differences occur
in neurocognitive performance between age, gender and
ADHD subtypes during MPH treatment. Analytical
results indicate that older patients (≥9 y/o) performedworse in many indices of TOVA than younger ones
(<9 y/o), and the older patients more significantly
improved in response time during treatment. However,
there were differences in some indices of TOVA at base-
line between age groups (data not shown). The effect of
age in neurocognitive performance is not necessarily im-
plying that older patients gained more from MPH treat-
ment than younger ones, and might be just a regression
to the mean. Moreover, male patients more significantly
improved in omission error and d’ than female ones dur-
ing MPH treatment. Despite similar findings found in a
previous study on the acute effects of MPH on TOVA
performance [13], a recent study found that gender
groups did not differ in neuropsychological performance
modulated by MPH [37]. The current studies regarding
the interaction of age, gender and MPH treatment
effects are still scarce. ADHD symptoms or sample se-
lection may confound differences in neurocognitive
effects between age or gender groups. Further study is
thus warranted on whether age and gender serve as pre-
dictors of MPH-related cognitive improvements.
Results of this study further demonstrate that patients
with ADHD-inattentive type had a higher ADHD com-
posite score in TOVA than patients with hyperactive-
impulsive or combined type. Meanwhile, MPH treatment
and ADHD subtypes did not interact with each other in
all TOVA indices. Subjects with hyperactive or combined
type of ADHD show more significantly improve in com-
mission errors than those with inattentive ADHD after
one dose of MPH [13]. However, several longitudinal
studies found that ADHD subtypes do not differ in MPH
enhanced cognitive performance [21-23]. We can infer
that the diversity of results from studies of MPH effects
on the neuropsychological profiles of subtypes of ADHD
patients may reflect variations in methodology. This study
does not support discriminated effectiveness in terms of
neurocognitive performance between ADHD subtypes.
Despite its contributions, this study has certain limita-
tions. First, a comparison group was absent. Exactly how
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environmental influence affects TOVA performance could
thus not be controlled. Longitudinal studies have shown
that there is a natural decline of symptoms with age, par-
ticularly the symptom of hyperactivity and impulsivity, in
children with ADHD [38]. Therefore, the improvements
in commission errors and d’ observed in our study might
be accounted for an age-related maturation. Second, the
subjects performed TOVA 3 times, with 6-month time
intervals between each TOVA tests. Practice effects may
be minimal, yet could not be completely ruled out. Third,
the treatment procedure of MPH was not strictly stan-
dardized, and drug adherence was not measured syste-
matically. Furthermore, a high rate of early termination,
variation of MPH dosage and possible inadequate drug ad-
herence may influence the estimation for the extent to
which MPH affects TOVA performance.
Conclusions
Using TOVA as a neuropsychological assessment scheme
revealed that impulsivity and perceptual sensitivity in
ADHD patients significantly improved during MPH
treatment for 12 months. Age and gender, yet not ADHD
subtypes, appear to influence the MPH treatment effects
in some indices of TOVA. A future study containing a
comparison group is suggested to confirm whether the
neurocognitive improvements are attributed to long-
term effects of MPH or natural maturation of patients.
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